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sustained virologic response atThe direct-acting antiviral combination glecaprevir/pibrentasvir has been approved by the
Food and Drug Administration for 8 weeks of treatment in treatment-naïve patients with
hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. We per-
formed an integrated analysis of data from trials to evaluate the overall efficacy and safety of 8
weeks of glecaprevir/pibrentasvir in treatment-naïve patients without cirrhosis or with
compensated cirrhosis.METHODS: We pooled data from 8 phase 2 or phase 3 trials of treatment-naïve patients with HCV genotype
1 to 6 infections, without cirrhosis or with compensated cirrhosis, who received 8 weeks of
glecaprevir/pibrentasvir.RESULTS: Of 1248 patients, 343 (27%) had cirrhosis. Most patients were white (80%) and had HCV
genotype 1 infection (47%) or genotype 3 infection (22%); the median age was 54 years.
Overall rates of sustained virologic response at post-treatment week 12 were 97.6% (1218 of
1248) in the intention to treat (ITT) and 99.3% (1218 of 1226) in the modified ITT populations.
When we excluded patients with genotype 3 infections with compensated cirrhosis (consistent
with the European label), rates of sustained virologic response at post-treatment week 12 were
97.6% in the ITT and 99.4% in the modified ITT populations. Eight virologic failures (7 in
patients without cirrhosis and 1 in a patient with cirrhosis) occurred in the ITT population.
Virologic failure was not associated with markers of advanced liver disease or populations of
interest (current alcohol use, opioid substitution therapy, history of injection-drug use, and
severe renal impairment). Treatment-emergent adverse events (AEs) occurred in 58% of
patients. The most frequent AEs (>10%) were headache (12%) and fatigue (12%). Serious AEs
and AEs that led to glecaprevir/pibrentasvir discontinuation were reported in 2% and less than
1% of patients, respectively.per: AE, adverse event; APRI, aspartate
tio index; DAA, direct-acting antiviral; G/P,
enotype; GTD3CC, population excluding
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October 2020 Glecaprevir/Pibrentasvir in HCV Infection 2545CONCLUSIONS: In a pooled analysis of data from 8 trials, we found that 8 weeks of treatment with glecaprevir/
pibrentasvir is efficacious and well tolerated in treatment-naïve patients with HCV genotype 1
to 6 infections, with or without cirrhosis.Keywords: DAA; Liver; Pangenotypic; Fibrosis; Panfibrotic.Hepatitis C virus (HCV) infection, one of the leadingcauses of chronic liver disease worldwide, can
lead to extensive fibrosis and cirrhosis and an increased
risk for developing hepatocellular carcinoma.1 In 2016,
the World Health Organization (WHO) established tar-
gets to eliminate HCV as a global health threat, including
reductions in HCV-related mortality by 65%, incidence
by 80%, increase in diagnosis to 90% of all HCV infec-
tions, and treatment of 80% of eligible persons by 2030.2
With the approval of direct-acting antivirals (DAAs)
beginning in 2014, the HCV population has evolved. DAA
treatment initially was prioritized for patients with more
advanced liver disease or those who had failed
interferon-based treatments previously.3,4 As a result of
this prioritization and increasing incidence among young
people who use drugs, the remaining HCV patient pop-
ulation has shifted rapidly to be younger and more often
treatment-naïve without cirrhosis.5,6 Based on a retro-
spective analysis from US academic and community
centers, 45% of treated patients had cirrhosis in 2014.
This percentage steadily decreased to 21% by the end of
2017.6 Because this represents only patients receiving
treatment, this percentage may be an overestimation of
the actual proportion of patients with cirrhosis because
many US publicly funded payers required that patients
have F3 or F4 fibrosis to be approved for treatment in
2017. This same analysis also saw the percentage of
patients with no prior treatment experience increase
from 56% in 2014 to 86% in 2017.
The DAA era also has facilitated the evolution of HCV
patient care, leading to increased awareness to improve
access to treatment to achieve elimination. A key factor
in the HCV elimination effort is expanding treatment to
primary care settings. As such, simplification of pre-
treatment evaluations and patient monitoring aim to
reduce new provider barriers to HCV management.7 In
the latter half of 2019, The American Association for the
Study of Liver Diseases and the Infectious Diseases
Society of America released guidelines with a simplified
treatment algorithm for treatment-naïve HCV patients
without cirrhosis or with compensated cirrhosis.8
Two highly effective pangenotypic DAA regimens are
recommended in each simplified algorithm, sofosbuvir/
velpatasvir9 and glecaprevir/pibrentasvir (G/P). These
guideline updates highlight a treatment paradigm shift
away from individualized treatment by HCV specialists to
broad dissemination of HCV care by nonspecialists who
may facilitate expansion of the HCV treater pool and HCV
elimination.10,11
The clinical trial program for the once-daily, all-oral,
fixed-dose DAA combination of glecaprevir, an NS3/4Aprotease inhibitor, and pibrentasvir, an NS5A inhibitor
(collectively G/P), compared an 8-week regimen with a
12-week regimen in patients chronically infected with
HCV genotypes (GT)1 to 6.12,13 An 8-week duration
initially was approved by the US Food and Drug
Administration and the European Medicines Agency in
2017 for treatment-naïve patients without cirrhosis, and
a 12-week duration was approved in treatment-naïve
patients with compensated cirrhosis.12 In recent real-
world studies, G/P achieved high sustained virologic
response at post-treatment week 12 (SVR12) rates
consistent with those observed in clinical trials.14–16
A recent phase 3b study (EXPEDITION-8) that eval-
uated G/P administered for 8 weeks in HCV treatment-
naïve patients with HCV GT1 to 6 infection and
compensated cirrhosis showed a high modified
intention-to-treat (mITT) SVR12 rate of 99.7%.17 This
finding led to a US label update in September 2019 and
an EU label update in March 2020 to shorten the treat-
ment duration from 12 to 8 weeks in treatment-naïve
patients with HCV and compensated cirrhosis across all
HCV genotypes (GT1–6).18,19 Currently, G/P is the only 8-
week pangenotypic treatment available for treatment-
naïve patients with chronic HCV irrespective of cirrhosis
status,10,18,20 meeting the needs of a changing HCV
patient population.5,6
The objective of this analysis was to assess the pooled
efficacy and safety of 8-week G/P treatment in HCV
treatment-naïve patients with chronic HCV GT1 to 6
infection without cirrhosis or with compensated
cirrhosis. Pre-approval and postapproval studies
included in this analysis enrolled diverse HCV patient
populations, including patients with HCV/human immu-
nodeficiency virus (HIV)-1 co-infection, all stages of
chronic kidney disease, or a history of injection-drug use.Methods
Patients and Study Design
This post hoc analysis was performed using pooled
data from 8 phase 2b, 3a, and 3b clinical trials of G/P, as
follows: SURVEYOR-121 (part 2; NCT02243280),




(NCT03069365), and EXPEDITION-817 (NCT03089944).
Patients were randomized or assigned to receive 8 weeks
of oral, once-daily G/P 300/120 mg.
What You Need to Know
Background
An analysis of data from multiple trials is needed
evaluate the overall efficacy and safety of 8 weeks of
glecaprevir/pibrentasvir in treatment-naïve patients
without cirrhosis or with compensated cirrhosis.
Findings
A pooled analysis of data from 8 trials found that 8
weeks of treatment with glecaprevir/pibrentasvir is
efficacious and well tolerated in treatment-naïve
patients with HCV genotype 1 to 6 infections, with or
without cirrhosis.
Implications for patient care
Patients with chronic HCV genotype 1 to 6 infections,
with or without cirrhosis, can be treated safely and
effectively with glecaprevir/pibrentasvir for
8 weeks.
2546 Zuckerman et al Clinical Gastroenterology and Hepatology Vol. 18, No. 11Details of the study design, patient population, and
outcomes of these trials have been published pre-
viously.17,21–26 In brief, patients were ages 18 years and
older, were diagnosed with chronic HCV GT1 to 6
infection, and were HCV treatment-naïve. Patients
without cirrhosis or with compensated cirrhosis were
included in this analysis. Cirrhosis assessment was based
on a liver biopsy, FibroScan (Echosens, Waltham, MA), or
a combination of FibroTest (BioPredictive, Paris, France)
and the aspartate aminotransferase to platelet ratio in-
dex (APRI). Cirrhosis status was determined within each
study protocol, and was not re-assessed for this analysis.
Cirrhosis was defined as a liver biopsy with a METAVIR
fibrosis score of 4 (or equivalent), a FibroScan result of
14.6 kPa or greater, or a FibroTest result of 0.75 or
higher with an APRI score greater than 2. Absence of
cirrhosis was defined by a liver biopsy with a METAVIR
fibrosis score of 3 or less (or equivalent), a FibroScan
result less than 12.5 kPa, or a FibroTest result less than
0.72 with an APRI score of 2 or less or a FibroTest result
of 0.48 or less with an APRI score of less than 1.Analysis Populations
The intention-to-treat (ITT) population included all
patients who received 1 or more doses of G/P. The mITT
population excluded patients with nonvirologic failure
(ie, patients who discontinued treatment without expe-
riencing virologic failure or who were lost to follow-up
evaluation).
Two data sets were used for this analysis: the
GT1 to 6 data set included all patients without cirrhosis
and those with compensated cirrhosis, and the popula-
tion excluding genotype 3–infected patients with
compensated cirrhosis (GTD3CC) data set (representa-
tive of the European Union label at the time of analysis).Efficacy Analysis
Efficacy, assessed as the percentage of patients with
SVR12, was determined in the ITT and the mITT patient
populations. SVR12 rates were calculated along with 2-
sided 95% CIs based on the Wilson score method.
SVR12 rates were evaluated in patient subgroups strat-
ified by clinical markers of advanced liver disease
including platelet count, albumin, fibrosis-4, and APRI.
SVR12 rates also were assessed in various pre-
specified patient subgroups categorized according to
baseline characteristics as follows: age, race, ethnicity,
body mass index, genotype, fibrosis stage, HCV RNA level,
recent injection-drug use (12 months prior), former
injection-drug use (>12 months prior), alcohol use,
concomitant proton pump inhibitor use, stable opioid
substitution therapy (OST), HIV co-infection, history of
diabetes, history of depression/bipolar disorder, and
severe renal impairment. Injection-drug use included all
illicit drugs, and recent injection-drug use was patient-reported and/or confirmed by positive urine drug
screen.
Safety Analysis
Treatment-emergent adverse events (AEs) were
analyzed in the ITT population and defined as AEs with
an onset after the start of G/P and no more than 30 days
after treatment. Clinical laboratory abnormalities in
alanine aminotransferase, aspartate aminotransferase,
and total bilirubin levels during the treatment period
were evaluated in the ITT population with available data.
Results
Patients and Demographics
The post hoc analysis of the GT1 to 6 data set (US
label–consistent data) included 1248 patients in the ITT
population, of whom 905 (73%) were noncirrhotic and
343 (27%) had compensated cirrhosis. Approximately
85% of patients were younger than age 65 years (median
age, 54 y), and 80% were white. Most of the patients had
HCV GT1 (47%) or GT3 (22%). The demographics and
clinical characteristics of these patients at baseline are
summarized in Table 1. The post hoc analysis of the
GTD3CC data set (European Union label–consistent data)
included 1185 patients in the ITT population.
Demographic characteristics of patients in the GTD3CC
data set were consistent with those in the GT1 to 6 data
set (Supplementary Table 1).
Nonvirologic failure was reported in 22 and 21
patients in the GT1 to 6 and GTD3CC data sets, respec-
tively (Table 2). Therefore, the mITT population included
1226 and 1164 patients, respectively.
Table 1. Demographics and Clinical Characteristics at Baseline: ITT Population, GT1 to 6 Data Set
GT1 to 6 treatment-naïve
Noncirrhotic (n ¼ 905) Cirrhotic (n ¼ 343) Overall (N ¼ 1248)
Male 492 (54.4) 217 (63.3) 709 (56.8)
Age, median, y 52.0 58.0 54.0
<65 y 800 (88.4) 257 (74.9) 1057 (84.7)
Race
White 708 (78.2) 285 (83.1) 993 (79.6)
Black 67 (7.4) 28 (8.2) 95 (7.6)
Asian 112 (12.4) 28 (8.2) 140 (11.2)
Othera 18 (2.0) 2 (0.6) 20 (1.6)
Ethnicity
Hispanic or Latino 92 (10.2) 43 (12.5) 135 (10.8)
Not Hispanic or Latino 813 (89.8) 300 (87.5) 1113 (89.2)
Mean BMI, kg/m2 26.3 28.3 26.8
30 kg/m2 160 (17.7) 101 (29.4) 261 (20.9)
HCV GT
1 352 (38.9) 231 (67.3) 583 (46.7)
2 202 (22.3) 26 (7.6) 228 (18.3)
3 217 (24.0) 63 (18.4) 280 (22.4)
4 53 (5.9) 13 (3.8) 66 (5.3)
5 19 (2.1) 1 (0.3) 20 (1.6)
6 62 (6.9) 9 (2.6) 71 (5.7)
Fibrosis stage
F0–F1 741/902 (82.2) 0 741/1245 (59.5)
F2 53/902 (5.9) 0 53/1245 (4.3)
F3 107/902 (11.9) 0 107/1245 (8.6)
F4 1/902 (0.1) 343 (100) 344/1245 (27.6)
HCV RNA, 1,000,000 IU/mL 547 (60.4) 231 (67.3) 778 (62.3)
Platelet count, <100  109/L 6 (0.7) 63 (18.4) 69 (5.5)
APRI 2 34/901 (3.8) 113/331 (34.1) 147/1232 (11.9)
FIB-4 3.25 46/901 (5.1) 168/331 (50.8) 214/1232 (17.4)
History of injection-drug useb
Recent (12 months prior) 22/624 (3.5) 4 (1.2) 26/967 (2.7)
>12 months prior 226/624 (36.2) 88 (25.7) 314/967 (32.5)
No history 376/624 (60.3) 251 (73.2) 627/967 (64.8)
Stable OST 69 (7.6) 27 (7.9) 96 (7.7)
HIV co-infection 121 (13.4) 0 121 (9.7)
History of diabetes 60 (6.6) 68 (19.8) 128 (10.3)
History of depression or bipolar disorder 206 (22.8) 11 (3.2) 217 (17.4)
Severe renal impairment 67 (7.4) 0 67 (5.4)
Concomitant PPI use 101 (11.2) 39 (11.4) 140 (11.2)
Alcohol use
Drinker 349 (38.6) 70 (20.4) 419 (33.6)
Ex-drinker 284 (31.4) 126 (36.7) 410 (32.9)
Nondrinker 267 (29.5) 144 (42.0) 411 (32.9)
Unknown 5 (0.6) 3 (0.9) 8 (0.6)
NOTE. Data are n (%) or n/N (%) unless otherwise stated; percentages are calculated from nonmissing values.
APRI, aspartate aminotransferase to platelet ratio index; BMI, body mass index; FIB-4, fibrosis-4; GT, genotype; HCV, hepatitis C virus; HIV, human immuno-
deficiency virus; ITT, intention-to-treat; OST, opioid substitution therapy; PPI, proton pump inhibitor.
aOther races include American Indian, Alaska native, multiple, native Hawaiian, and other Pacific Islander categories.
bSURVEYOR-1 and -2 trials did not capture this information and are excluded from this assessment.
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In the GT1 to 6 data set, the ITT SVR12 rate was
97.6% (95% CI, 96.6–98.3) and did not differ by
cirrhosis status: 97.6% (95% CI, 96.3–98.4) in patients
without cirrhosis and 97.7% (95% CI, 95.5–98.8) in
patients with compensated cirrhosis. In the mITT popu-
lation, the SVR12 rates were 99.2% (95% CI, 98.4–99.6)
in the noncirrhotic group, 99.7% (95% CI, 98.3–99.9) inthe compensated cirrhosis group, and 99.3% (95% CI,
98.7–99.7) overall (Figure 1). Similar results were
observed in the GTD3CC data set, with SVR12 rates
greater than 97% and greater than 99% for the ITT and
mITT populations, respectively (Supplementary
Figure 1).
In an examination of clinical markers of advanced
liver disease, SVR12 rates were greater than 95%. In the
ITT population, SVR12 rates were 95.7% and 96.6%
Table 2. Reasons for SVR12 Nonresponse: ITT Population,
GT1 to 6 Data Set
Reasons for
nonresponse, n (%)









1 (0.1) 0 1 (<0.1)
Relapsea 6/890 (0.7) 1/336 (0.3) 7/1226 (0.6)
Nonvirologic failure 15 (1.7) 7 (2.0) 22 (1.8)
Study-drug
discontinuation
6 (0.7) 1 (0.3) 7 (0.6)
Lost to follow-up
evaluation
9 (1.0) 6 (1.7) 15 (1.2)
GT, genotype; ITT, intention-to-treat; SVR12, sustained virologic response at
post-treatment week 12.
aDenominator includes patients who completed treatment with hepatitis C virus
RNA less than the lower limit of quantification at the end of treatment and had
post-treatment hepatitis C virus RNA data.
2548 Zuckerman et al Clinical Gastroenterology and Hepatology Vol. 18, No. 11among patients with platelet counts less than 100  109/L
and albumin levels less than 3.5 g/dL, respectively; the
mITT SVR12 rates were 98.5% and 100%, respectively
(Figure 2). SVR12 rates in subgroups defined by clinical
markers of advanced liver disease in the GTD3CC data set
were similar to those observed in the GT1 to 6 data set
(Supplementary Figure 2).
In the GT1 to 6 data set, virologic failure was
observed in 1 of 343 patients (0.3%) with compensated
cirrhosis (GT3) and in 7 of 905 patients (0.8%) without
cirrhosis (6 GT3 and 1 GT5) in the ITT population; of
these 8 cases of virologic failure, 7 were relapses and 1
was on-treatment virologic failure (Table 2). For GT3
patients in the mITT population with available resistance
data (using a 15% threshold), 23 of 270 (8.5%) had
A30K substitutions at baseline, 4 of whom experienced
virologic failure; additional resistance details of these
virologic failures have been reported previously.19 In
addition, 14 of 270 (5.2%) GT3 patients had Y93H sub-
stitutions at baseline; none of these patients experienced
virologic failure. In the GTD3CC data set, there were 6
relapses and 1 on-treatment virologic failure
(Supplementary Table 2). The rate of nonvirologic failure
was less than 2% in both the GT1 to 6 data set (Table 2)
and the GTD3CC data set (Supplementary Table 2). In
both data sets, roughly one third of the patients with
nonvirologic failure discontinued G/P prematurely; the
rest were lost to follow-up evaluation.Efficacy by Baseline Characteristics
ITT SVR12 rates were greater than 95% across
assessed baseline characteristics, with the exception of
recent injection-drug use (88.5%; 23 of 26) and F3
fibrosis (93.5%; 100 of 107) (Table 3); however, the
majority of these non-SVRs were owing to missing SVR12
data rather than virologic failure. As such, SVR12 rateswere very high in the mITT population (95%)
(Table 3), irrespective of baseline characteristics,
including history of injection-drug use, fibrosis score,
alcohol use, OST, and HIV co-infection. In the GTD3CC
data set, mITT SVR12 rates across all subgroups also
were high. Supplementary Table 3 shows SVR12 rates for
the GTD3CC mITT and ITT populations. SVR12 rates by
genotype in treatment-naïve, noncirrhotic patients are
shown for the ITT and mITT populations in
Supplementary Table 4.
Safety
In the GT1 to 6 data set, the rate of any AEs was 58%,
with the most common AEs (10%) being headache
(12%) and fatigue (12%). The rate of serious AEs was
2%. None of the serious AEs were considered related to
G/P treatment. AEs leading to premature G/P discon-
tinuation occurred in 2 (<1%) patients (all non-
cirrhotic); both were serious AEs with no reasonable
possibility of being related to G/P treatment (adenocar-
cinoma and ileus). One patient with a history of diabetic
nephropathy and moderate ascites at screening enrolled
as a protocol violation and experienced a nonserious
event of worsening ascites (grade 1) on day 8, which was
ongoing at the end of the study. Six patients (<1%)
experienced hepatic laboratory abnormalities of grade 3
severity or higher in levels of alanine aminotransferase
(n ¼ 1), aspartate aminotransferase increase (n ¼ 1), or
total bilirubin (n ¼ 4). None of the cases were consistent
with drug-induced liver injury (Table 4). Two patients
without cirrhosis died; 1 death was the result of
adenocarcinoma and the other was owing to an acci-
dental overdose on post-treatment day 77; both were
considered not related to study-drug treatment.
Safety results in the GTD3CC data set were similar to
those in the GT1 to 6 data set: AEs were reported in 59%
of patients, and the rates of AEs leading to discontinua-
tion (<1%), serious AEs (3%), and serious AEs leading to
discontinuation (<1%) were low (Supplementary
Table 5). There were no serious AEs related to G/P
treatment. The 2 deaths observed in the GT1 to 6 data set
were captured in this data set as well.
Discussion
This post hoc analysis shows that treatment with G/P
for 8 weeks is highly efficacious (GT1–6 data set: mITT
SVR12 >99%; ITT SVR12, >97%) in HCV treatment-
naïve patients with chronic HCV GT1 to 6 infection
regardless of cirrhosis status, with a virologic failure rate
of less than 0.8%. The analysis in the GTD3CC data set
showed similar results: SVR12 rates were high (>99% in
the mITT population and >97% in the ITT population)
regardless of cirrhosis status. Similarly, effectiveness
data from real-world studies of 8-week treatment with
G/P in treatment-naïve populations are consistent with
Figure 1. SVR12 rates after glecaprevir/pibrentasvir treatment for 8 weeks by cirrhosis status (GT1–6 data set). Numbers
represent the number of patients with SVR12/total number of patients in each group. Error bars represent 95% CIs. *The mITT
population excluded patients with nonvirologic failure. GT, genotype; ITT, intention-to-treat; mITT, modified intention-to-treat;
SVR12, sustained virologic response at post-treatment week 12.
October 2020 Glecaprevir/Pibrentasvir in HCV Infection 2549the rates of SVR12 observed in this analysis.15,27–31
These high SVR12 rates support the product labeling
that recommends the use of G/P for 8 weeks in treat-
ment-naïve HCV patients without cirrhosis or with
compensated cirrhosis, regardless of genotype.
The subgroup analysis conducted in the present study
confirmed that G/P treatment resulted in high mITTFigure 2. SVR12 rates
after glecaprevir/pibrentasvir
treatment for 8 weeks by
clinical markers of
advanced liver disease
(GT1–6 data set): (A) ITT
and (B) mITT population*.
Numbers represent the
number of patients with
SVR12/total number of
patients in each group.
Error bars represent 95%
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week 12.SVR12 (95%) rates across all patient subgroups cate-
gorized by clinical markers of advanced liver disease and
baseline characteristics, including concomitant proton
pump inhibitor, OST, and history of injection-drug use.
However, in both the GT1 to 6 and GTD3CC data sets,
patients with a recent history of injection-drug use had
slightly lower ITT SVR12 rates, although there were no
Table 3. SVR12 Rates After G/P Treatment for 8 Weeks by Subgroups of Interest: GT1 to 6 Data Set
GT1 to 6 treatment-naive
ITT mITTa
n/N (%) 95% CI n/N (%) 95% CI
<65 y 1033/1057 (97.7) 96.6–98.5 1033/1041 (99.2) 98.5–99.6
65 y 185/191 (96.9) 93.3–98.6 185/185 (100) 98.0–100
Black 92/95 (96.8) 91.1–98.9 92/92 (100) 96.0–100
Non-black 1126/1153 (97.7) 96.6–98.4 1126/1134 (99.3) 98.6–99.6
Hispanic or Latino 133/135 (98.5) 94.8–99.6 133/134 (99.3) 95.9–99.9
Not Hispanic or Latino 1085/1113 (97.5) 96.4–98.3 1085/1092 (99.4) 98.7–99.7
BMI <30 kg/m2 962/987 (97.5) 96.3–98.3 962/970 (99.2) 98.4–99.6
BMI 30 kg/m2 256/261 (98.1) 95.6–99.2 256/256 (100) 98.5–100
HCV GT1 573/583 (98.3) 96.9–99.1 573/573 (100) 99.3–100
HCV GT2 226/228 (99.1) 96.9–99.8 226/226 (100) 98.3–100
HCV GT3 267/280 (95.4) 92.2–97.3 267/274 (97.4) 94.8–98.8
HCV GT4 63/66 (95.5) 87.5–98.4 63/63 (100) 94.3–100
HCV GT5 19/20 (95.0) 76.4–99.1 19/20 (95.0) 76.4–99.1
HCV GT6 70/71 (98.6) 92.4–99.8 70/70 (100) 94.8–100
Fibrosis stage F0–1 728/741 (98.2) 97.0–99.0 728/730 (99.7) 99.0–99.9
Fibrosis stage F2 51/53 (96.2) 87.2–99.0 51/53 (96.2) 87.2–99.0
Fibrosis stage F3 100/107 (93.5) 87.1–96.8 100/103 (97.1) 91.8–99.0
Fibrosis stage F4 336/344 (97.7) 95.5–98.8 336/337 (99.7) 98.3–99.9
HCV RNA, <1,000,000 IU/mL 460/470 (97.9) 96.1–98.8 460/461 (99.8) 98.8–100
HCV RNA, 1,000,000 IU/mL 758/778 (97.4) 96.1–98.3 758/765 (99.1) 98.1–99.6
Recent injection-drug use (12 months prior)b 23/26 (88.5) 71.0–96.0 23/23 (100) 85.7–100
Injection-drug use >12 months priorb 304/314 (96.8) 94.2–98.3 304/308 (98.7) 96.7–99.5
No history of injection-drug priorb 618/627 (98.6) 97.3–99.2 618/622 (99.4) 98.4–99.7
On stable OST 93/96 (96.9) 91.2–98.9 93/93 (100) 96.0–100
Not on stable OST 1125/1152 (97.7) 96.6–98.4 1125/1133 (99.3) 98.6–99.6
HIV co-infection 120/121 (99.2) 95.5–99.9 120/120 (100) 96.9–100
No HIV co-infection 1098/1127 (97.4) 96.3–98.2 1098/1106 (99.3) 98.6–99.6
History of diabetes 125/128 (97.7) 93.3–99.2 125/126 (99.2) 95.6–99.9
No history of diabetes 1093/1120 (97.6) 96.5–98.3 1093/1100 (99.4) 98.7–99.7
History of depression/bipolar disorder 212/217 (97.7) 94.7–99.0 212/212 (100) 98.2–100
No history of depression/bipolar disorder 1006/1031 (97.6) 96.4–98.4 1006/1014 (99.2) 98.5–99.6
Concomitant PPI 136/140 (97.1) 92.9–98.9 136/136 (100) 97.3–100
No concomitant PPI 1082/1108 (97.7) 96.6–98.4 1082/1090 (99.3) 98.6–99.6
Severe renal impairment 65/67 (97.0) 89.8–99.2 65/65 (100) 94.4–100
No severe renal impairment 1153/1181 (97.6) 96.6–98.4 1153/1161 (99.3) 98.6–99.7
Drinker 409/419 (97.6) 95.7–98.7 409/412 (99.3) 97.9–99.8
Ex-drinker 395/410 (96.3) 94.1–97.8 395/400 (98.8) 97.1–99.5
Nondrinker 406/411 (98.8) 97.2–99.5 406/406 (100) 99.1–100
NOTE. n/N, number of patients with SVR12/ total number of patients in each subgroup.
BMI, body mass index; G/P, glecaprevir/pibrentasvir; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; ITT, intention-to-treat; mITT,
modified intention-to-treat; OST, opioid substitution therapy; PPI, proton-pump inhibitor; SVR12, sustained virologic response at post-treatment week 12.
amITT population excluded patients with nonvirologic failure.
bSURVEYOR-1 and SURVEYOR-2 trials did not capture this information, thus they were excluded from this assessment.
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limited because of small sample sizes, but remain
consistent with previous results.32 Historically, patients
with certain baseline disease or viral characteristics were
considered to be harder to cure.33,34 In the present
analysis, none of the evaluated baseline characteristics
affected the rate of virologic failure. Achieving high
SVR12 rates with the G/P 8-week regimen regardless of
HCV genotype and patient baseline characteristics might
eliminate the need for genotyping and other baseline
assessments before therapy.11 The updated American
Association for the Study of Liver Diseases and theInfectious Diseases Society of America simplified treat-
ment algorithm does not recommend any genotype-
specific assessments in patients with HCV GT1 to 6 and
compensated cirrhosis before the initiation of HCV treat-
ment with G/P, which is not the case with sofosbuvir/
velpatasvir.10 High SVR12 rates observed in the present
integrated analysis across all genotypes validate these
recommendations with respect to G/P treatment.
Treatment with G/P was well tolerated; treatment-
related serious AEs, discontinuations because of AEs,
and laboratory abnormalities of grade 3 or higher
severity were rare and not consistent with drug-induced
Table 4. Treatment-Emergent Adverse Events and
Postbaseline Clinical Laboratory Abnormalities: ITT
Population; GT1 to 6 Data Set








Any AE 563 (62.2) 158 (46.1) 721 (57.8)
Any serious AE 24 (2.7) 6 (1.7) 30 (2.4)
Any serious AE possibly
related to G/P
0 0 0
Any AE leading to G/P
discontinuation
2 (0.2) 0 2 (0.2)
Any serious AE leading to
G/P discontinuation
2 (0.2) 0 2 (0.2)
Deathsa 2 (0.2) 0 2 (0.2)
AEs in 10% in any
group
Headache 120 (13.3) 28 (8.2) 148 (11.9)








Grade 3 1/903 (0.1) 0/342 1/1245
(<0.1)
Total bilirubin
Grade 3 4/903 (0.4) 0/342 4/1245 (0.3)
n/N, number of patients with respective parameter/number of patients with
available data.
AE, treatment-emergent adverse event; G/P, glecaprevir/pibrentasvir;
GT, genotype; ITT, intention-to-treat.
aIncludes non–treatment-emergent deaths
October 2020 Glecaprevir/Pibrentasvir in HCV Infection 2551liver injury. No new safety signals were observed in the
current analysis.
There were limitations to this analysis that are
inherent to its design. Because this is a post hoc analysis,
it does not have the statistical power to compare
patient groups. In addition, not all of the studies included
in the analysis reported the same data, specifically
SURVEYOR-1 and SURVEYOR-2 did not capture data on
whether patients had a history of injection-drug use 12
months or fewer prior or more than 12 months prior. A
further limitation was the low number of patients in
some subgroups, for example, patients with recent
injection-drug use and patients with HCV GT5.
In conclusion, the results of this analysis show that
G/P for 8 weeks is efficacious in treating treatment-naïve
patients, who comprise the current majority of infected
patients with HCV. Considering the high overall mITT
SVR12 rate and the very low number of virologic failures,
there would be little benefit in trying to identify negative
predictors or a subpopulation with low SVR, adding to
the evidence that treatment with 8 weeks of G/P
potentially simplifies pretreatment assessment.Furthermore, the short treatment duration may help the
effort to improve patient adherence to treatment, reduce
treatment burden, and support elimination efforts.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2020.06.044.References
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Supplementary Figure 1. SVR12 rates after G/P treatment for 8 weeks by cirrhosis status (GTD3CC data set). Numbers
represent the number of patients with SVR12/total number of patients in each group. Error bars represent 95% CIs. *mITT
population excluded patients with nonvirologic failure. G/P, glecaprevir/pibrentasvir; GTD3CC, population excluding genotype
3–infected patients with compensated cirrhosis; ITT, intention-to-treat; mITT, modified intention-to-treat; SVR12, sustained
virologic response at post-treatment week 12.
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Supplementary
Figure 2. SVR12 rates after G/P
treatment for 8 weeks by clin-
ical markers of advanced liver
disease (GTD3CC data set): (A)
ITT and (B) mITT population*.
Numbers represent the number
of patients with SVR12 and the
total number of patients in each
group. Error bars represent
95% CIs. *The mITT population
excluded patients with non-
virologic failure. APRI, aspar-
tate aminotransferase to
platelet ratio index; FIB-4,
fibrosis-4; G/P, glecaprevir/
pibrentasvir; GTD3CC, popula-
tion excluding genotype 3–
infected patients with compen-
sated cirrhosis; ITT, intention-
to-treat; mITT, modified
intention-to-treat; SVR12, sus-
tained virologic response at
post-treatment week 12.
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Supplementary Table 1. Demographics and Clinical Characteristics at Baseline: ITT Population, GTD3CC Data Set
Treatment-naïve
GT1 to 6
Noncirrhotic (n ¼ 905)
GT1, 2, 4–6
cirrhotic (n ¼ 280)
Overall
(N ¼ 1185)
Male 492 (54.4) 168 (60.0) 660 (55.7)
Age, median, y 52.0 60.0 54.0
<65 y 800 (88.4) 196 (70.0) 996 (84.1)
Race
White 708 (78.2) 223 (79.6) 931 (78.6)
Black 67 (7.4) 27 (9.6) 94 (7.9)
Asian 112 (12.4) 28 (10.0) 140 (11.8)
Othera 18 (2.0) 2 (0.7) 20 (1.7)
Ethnicity
Hispanic or Latino 92 (10.2) 35 (12.5) 127 (10.7)
Not Hispanic or Latino 813 (89.8) 245 (87.5) 1058 (89.3)
BMI, mean, kg/m2 26.3 28.2 26.7
30 kg/m2 160 (17.7) 81 (28.9) 241 (20.3)
HCV GT
1 352 (38.9) 231 (82.5) 583 (49.2)
2 202 (22.3) 26 (9.3) 228 (19.2)
3 217 (24.0) 0 217 (18.3)
4 53 (5.9) 13 (4.6) 66 (5.6)
5 19 (2.1) 1 (0.4) 20 (1.7)
6 62 (6.9) 9 (3.2) 71 (6.0)
Fibrosis stage
F0–F1 741/902 (82.2) 0 741/1182 (62.7)
F2 53/902 (5.9) 0 53/1182 (4.5)
F3 107/902 (11.9) 0 107/1182 (9.1)
F4 1/902 (0.1) 280 (100) 281/1182 (23.8)
HCV RNA, 1,000,000 IU/mL 547 (60.4) 190 (67.9) 737 (62.2)
Platelet count, <100  109/L 6 (0.7) 48 (17.1) 54 (4.6)
APRI, 2 34/901 (3.8) 92/270 (34.1) 126/1171 (10.8)
FIB-4, 3.25 46/901 (5.1) 141/270 (52.2) 187/1171 (16.0)
History of injection-drug useb
Recent, 12 months prior 22/624 (3.5) 2 (0.7) 24/904 (2.7)
>12 months prior 226/624 (36.2) 70 (25.0) 296/904 (32.7)
No history 376/624 (60.3) 208 (74.3) 584/904 (64.6)
Stable OST 69 (7.6) 17 (6.1) 86 (7.3)
HIV co-infection 121 (13.4) 0 121 (10.2)
History of diabetes 60 (6.6) 56 (20.0) 116 (9.8)
History of depression or bipolar disorder 206 (22.8) 8 (2.9) 214 (18.1)
Severe renal impairment 67 (7.4) 0 67 (5.7)
Concomitant PPI use 101 (11.2) 31 (11.1) 132 (11.1)
Alcohol use
Drinker 349 (38.6) 52 (18.6) 401 (33.8)
Ex-drinker 284 (31.4) 107 (38.2) 391 (33.0)
Nondrinker 267 (29.5) 119 (42.5) 386 (32.6)
Unknown 5 (0.6) 2 (0.7) 7 (0.6)
NOTE. Data are n (%) or n/N (%) unless otherwise stated; percentages are calculated from nonmissing values.
APRI, aspartate aminotransferase to platelet ratio index; BMI, body mass index; FIB-4, fibrosis-4; GT, genotype; GTD3CC, population excluding genotype
3–infected patients with compensated cirrhosis; HCV, hepatitis C virus; HIV, human immunodeficiency virus; ITT, intention-to-treat; OST, opioid substitution
therapy; PPI, proton pump inhibitor.
aOther races include American Indian, Alaska native, multiple, native Hawaiian, and other Pacific Islander categories.
bSURVEYOR-1 and SURVEYOR-2 trials did not capture this information and were excluded from this assessment.
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Supplementary Table 2. Reasons for SVR12 Nonresponse: ITT Population, GTD3CC Data Set





cirrhotic (n ¼ 280)
Overall
(N ¼ 1185)
On-treatment virologic failure 1 (0.1) 0 1 (<0.1)
Relapsea 6/890 (0.7) 0/274 6/1164 (0.5)
Nonvirologic failure 15 (1.7) 6 (2.1) 21 (1.8)
Study-drug discontinuation 6 (0.7) 1 (0.4) 7 (0.6)
Lost to follow-up evaluation 9 (1.0) 5 (1.8) 14 (1.2)
GT, genotype; GTD3CC, population excluding genotype 3–infected patients with compensated cirrhosis; ITT, intention-to-treat; SVR12, sustained virologic
response post-treatment week 12.
aDenominator includes patients who completed treatment with hepatitis C virus RNA less than the lower limit of quantification at the end of treatment and had
post-treatment hepatitis C virus RNA data.
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Supplementary Table 3. SVR12 Rates After G/P Treatment for 8 Weeks by Subgroups of Interest: GTD3CC Data Set
Treatment-naïve
ITT mITTa
n/N (%) 95% CI n/N (%) 95% CI
<65 y 975/996 (97.9) 96.8–98.6 975/982 (99.3) 98.5–99.7
65 y 182/189 (96.3) 92.6–98.2 182/182 (100) 97.9–100
Black 91/94 (96.8) 91.0–98.9 91/91 (100) 95.9–100
Non-black 1066/1091 (97.7) 96.6–98.4 1066/1073 (99.3) 98.7–99.7
Hispanic or Latino 125/127 (98.4) 94.4–99.6 125/126 (99.2) 95.6–99.9
Not Hispanic or Latino 1032/1058 (97.5) 96.4–98.3 1032/1038 (99.4) 98.7–99.7
BMI, <30 kg/m2 920/944 (97.5) 96.2–98.3 920/927 (99.2) 98.4–99.6
BMI, 30 kg/m2 237/241 (98.3) 95.8–99.4 237/237 (100) 98.4–100
HCV GT1 572/583 (98.1) 96.7–98.9 572/572 (100) 99.3–100
HCV GT2 226/228 (99.1) 96.9–99.8 226/226 (100) 98.3–100
HCV GT3 207/217 (95.4) 91.7–97.5 207/213 (97.2) 94.0–98.7
HCV GT4 63/66 (95.5) 87.5–98.4 63/63 (100) 94.3–100
HCV GT5 19/20 (95.0) 76.4–99.1 19/20 (95.0) 76.4–99.1
HCV GT6 70/71 (98.6) 92.4–99.8 70/70 (100) 94.8–100
Fibrosis stage F0–F1 728/741 (98.2) 97.0–99.0 728/730 (99.7) 99.0–99.9
Fibrosis stage F2 51/53 (96.2) 87.2–99.0 51/53 (96.2) 87.2–99.0
Fibrosis stage F3 100/107 (93.5) 87.1–96.8 100/103 (97.1) 91.8–99.0
Fibrosis stage F4 275/281 (97.9) 95.4–99.0 275/275 (100) 98.6–100
HCV RNA, <1,000,000 IU/mL 439/448 (98.0) 96.2–98.9 439/440 (99.8) 98.7–100
HCV RNA, 1,000,000 IU/mL 718/737 (97.4) 96.0–98.3 718/724 (99.2) 98.2–99.6
Recent injection-drug use, 12 months priorb 21/24 (87.5) 69.0–95.7 21/21 (100) 84.5–100
Injection-drug use, >12 months priorb 287/296 (97.0) 94.3–98.4 287/291 (98.6) 96.5–99.5
No history of injection-drug priorb 576/584 (98.6) 97.3–99.3 576/579 (99.5) 98.5–99.8
On stable OST 83/86 (96.5) 90.2–98.8 83/83 (100) 95.6–100
Not on stable OST 1074/1099 (97.7) 96.7–98.5 1074/1081 (99.4) 98.7–99.7
HIV co-infection 120/121 (99.2) 95.5–99.9 120/120 (100) 96.9–100
No HIV co-infection 1037/1064 (97.5) 96.3–98.3 1037/1044 (99.3) 98.6–99.7
History of diabetes 114/116 (98.3) 93.9–99.5 114/114 (100) 96.7–100
No history of diabetes 1043/1069 (97.6) 96.5–98.3 1043/1050 (99.3) 98.6–99.7
History of depression/bipolar disorder 209/214 (97.7) 94.6–99.0 209/209 (100) 98.2–100
No history of depression/bipolar disorder 948/971 (97.6) 96.5–98.4 948/955 (99.3) 98.5–99.6
Concomitant PPI 129/132 (97.7) 93.5–99.2 129/129 (100) 97.1–100
No concomitant PPI 1028/1053 (97.6) 96.5–98.4 1028/1035 (99.3) 98.6–99.7
Severe renal impairment 65/67 (97.0) 89.8–99.2 65/65 (100) 94.4–100
No severe renal impairment 1092/1118 (97.7) 96.6–98.4 1092/1099 (99.4) 98.7–99.7
Drinker 391/401 (97.5) 95.5–98.6 391/394 (99.2) 97.8–99.7
Ex-drinker 377/391 (96.4) 94.1–97.9 377/381 (99.0) 97.3–99.6
Nondrinker 382/386 (99.0) 97.4–99.6 382/382 (100) 99.0–100
NOTE. n/N shows the number of patients with SVR12/total number of patients in each subgroup.
BMI, body mass index; G/P, glecaprevir/pibrentasvir; GT, genotype; GTD3CC, population excluding genotype 3–infected patients with compensated cirrhosis;
HCV, hepatitis C virus; HIV, human immunodeficiency virus; ITT, intention-to-treat; mITT, modified intention-to-treat; OST, opioid substitution therapy; PPI,
proton-pump inhibitor; SVR12, sustained virologic response at post-treatment week 12.
amITT population excluded patients with nonvirologic failure.
bSURVEYOR-1 and SURVEYOR-2 trials did not capture this information, thus they were excluded from this assessment.
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Supplementary Table 4. SVR12 Rates After G/P Treatment




n/N (%) 95% CI n/N (%) 95% CI
GT1 347/352 (98.6) 96.7–99.4 347/347 (100) 98.9–100
GT2 200/202 (99.0) 96.5–99.7 200/200 (100) 98.1–100
GT3 207/217 (95.4) 91.7–97.5 207/213 (97.2) 94.0–98.7
GT4 50/53 (94.3) 84.6–98.1 50/50 (100) 92.9–100
GT5 18/19 (94.7) 75.4–99.1 18/19 (94.7) 75.4–99.1
GT6 61/62 (98.4) 91.4–99.7 61/61 (100) 94.1–100
Overall 883/905 (97.6) 96.3–98.4 883/890 (99.2) 98.4–99.6
NOTE. n/N shows the number of patients with SVR12/total number of patients
in each subgroup.
G/P, glecaprevir/pibrentasvir; GT, genotype; GTD3CC, population excluding
genotype 3–infected patients with compensated cirrhosis; ITT, intention-to-
treat; mITT, modified intention-to-treat; SVR12, sustained virologic response
at post-treatment week 12.
aPopulation is the same in the GT1 to 6 and GTD3CC data sets.
bmITT population excluded patients with nonvirologic failure.
Supplementary Table 5. Treatment-Emergent Adverse Events and Postbaseline Clinical Laboratory Abnormalities: ITT
Population, GTD3CC Data Set
Treatment-naïve
GT1–6
noncirrhotic (n ¼ 905)
GT1, 2, 4–6




Any AE 563 (62.2) 134 (47.9) 697 (58.8)
Any serious AE 24 (2.7) 6 (2.1) 30 (2.5)
Any serious AE possibly related to G/P 0 0 0
Any AE leading to G/P discontinuation 2 (0.2) 0 2 (0.2)
Any serious AE leading to G/P discontinuation 2 (0.2) 0 2 (0.2)
Deathsa 2 (0.2) 0 2 (0.2)
AEs in 10% patients in any group
Headache 120 (13.3) 23 (8.2) 143 (12.1)
Fatigue 115 (12.7) 24 (8.6) 139 (11.7)
Laboratory abnormalities, n/N (%)
Alanine aminotransferase
Grade 3 0/903 0/279 0/1182
Aspartate aminotransferase
Grade 3 1/903 (0.1) 0/279 1/1182 (<0.1)
Total bilirubin
Grade 3 4/903 (0.4) 0/279 4/1182 (0.3)
NOTE. n/N shows number of patients with respective parameter/number of patients with available data.
AE, adverse event; GT, genotype; G/P, glecaprevir pibrentasvir; GTD3CC, population excluding genotype 3–infected patients with compensated cirrhosis; ITT,
intention-to-treat.
aIncludes non–treatment-emergent deaths.
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